Key result
ARB treatment prevented increases in systolic BP, renal Ang II, and renal injury in spontaneously hypertensive rats, whereas triple therapy prevented hypertension but failed to prevent renal injury.
Why the study?
Does ARB or triple antihypertensive therapy prevent renal injury and reduce intrarenal angiotensinogen in spontaneously hypertensive rats?
Population
Spontaneously hypertensive rats and Wistar-Kyoto rats at 7 or 14 weeks of age
Comparison
Angiotensin II type 1 receptor blocker or triple… vs Untreated SHR and WKY rats
Design
Preclinical
Follow-up
7 weeks (from week 7 to 14 of age)
Authors
Loading...
Augmented intrarenal angiotensinogen may drive renal Ang II injury in SHR; leaves open translation to human hypertension.
Does ARB or triple antihypertensive therapy prevent renal injury and reduce intrarenal angiotensinogen in spontaneously hypertensive rats?
ARB therapy, but not standard triple antihypertensive therapy, prevents early renal injury in spontaneously hypertensive rats by reducing intrarenal angiotensinogen and Ang II levels.
Kobori et al. (2005) studied Hypertension and renal injury (n=48). Angiotensin II type 1 receptor blocker (olmesartan) or triple therapy (hydralazine, reserpine, hydrochlorothiazide) vs. Untreated SHR and WKY rats was evaluated on Systolic blood pressure, renal Angiotensin II levels, and renal injury parameters. ARB treatment prevented increases in systolic BP, renal Ang II, and renal injury in spontaneously hypertensive rats, whereas triple therapy prevented hypertension but failed to prevent renal injury.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: